Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Nektar Therapeutics
Nektar Therapeutics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Ingredients
Therapeutic: rezpegaldesleukin for dermatitis
Atopic dermatitis remains an unmet medical need, with better and more effective treatments still required for the one in 10 people who are affected
Regulatory
Anticancer agent – etirinotecan pegol
Nektar Therapeutics has developed a pegylated tetrameric derivative of irinotecan that is designed to preferentially penetrate tumour vasculature ahead of normal vasculature
Pharmaceutical
Ivan Gergel becomes SVP, Drug Development & Chief Medical Officer at Nektar Therapeutics
Joins the company from Endo Pharmaceuticals
Regulatory
Opioid-induced constipation – naloxegol
About half of all patients taking opioids commonly experience constipation
Subscribe now